Johnson & Johnson plans to buy eye disease biotech company Ollin Biosciences for up to $3.4 billion. Under the agreement, Johnson & Johnson may pay Ollin supporters $2.2 billion in upfront cash, as well as another $1.2 billion in potential milestone payments.

Zhitongcaijing · 5d ago
Johnson & Johnson plans to buy eye disease biotech company Ollin Biosciences for up to $3.4 billion. Under the agreement, Johnson & Johnson may pay Ollin supporters $2.2 billion in upfront cash, as well as another $1.2 billion in potential milestone payments.